Saturday, November 02, 2019 5:56:16 PM
2. I reviewed the company's updated presentation. The last time I'd looked, they'd been guiding for Fragile X readout in Q4 or close to year end (perhaps the riskiest but least impactful of the 4 expected readouts over the next year). However, now they are guiding for it in early 2020 and I remind members that the ARCADE readout for soticlestat in CDKL5 Deficiency Disorder / Dup15q Syndrome is expected in Q1. I have higher conviction for this second readout, considering promising results we reviewed previously for the ENDYMION open label extension trial.
Given this change, to my eyes it makes it less feasible to wait for the Fragile X readout to get in prior to ARCADE. As preclinical rationale for OV101 appears intriguing and data in FXS mice has shown normalization of certain aspects of Fragile X (anxiety, irritability, repetitive behaviors, hyperactivity), I don't mind being exposed to both readouts (with Angelman to follow midyear).
Market capitalization of around $125 million seems quite reasonable relative to substantial market opportunities being targeted and multi-faceted neurology pipeline (cash position boosted by secondary as well). This is primarily a catalyst idea, as several data events loom in the near to medium term (OV101 in Fragile X and Angelman, soticlestat in phase 2 ARCADE study and phase 2 ELEKTRA trial). OV101 is the only drug in development for Angelman Syndrome, and management appears to have much confidence in achieving the same CGI-I endpoint as the prior mid-stage study (FDA gave them green light to file for registration if they can do so). Soticlestat, 50-50 partnered with Takeda, has a unique mechanism of action that not only crushes seizures but also potentially heals the brain. The asset is both first-in-class and only-in-class, is targeting a large opportunity in rare epilepsies, and has shown impressive seizure reduction in prior trials (caveat for low N). ENDYMION extension data provided another element of derisking as a group of incredibly difficult to treat patients experienced increased seizure reduction with prolonged treatment. See my September article. Time Frame For Upside = 6 to 12 months as multiple data readouts come to pass (Catalyst Idea).
Recent OVID News
- Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 01:24:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 01:20:05 PM
- Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/08/2024 01:00:00 PM
- Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:00:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 10:56:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 10:53:07 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 04:10:32 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 11:06:38 AM
- Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 10:08:19 PM
- Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023) • GlobeNewswire Inc. • 12/01/2023 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/16/2023 05:15:10 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/15/2023 09:11:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/03/2023 08:08:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/03/2023 12:13:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 12:10:27 PM
- Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates • GlobeNewswire Inc. • 11/03/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/18/2023 12:04:53 PM
- Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026 • GlobeNewswire Inc. • 10/18/2023 12:00:00 PM
- Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit • GlobeNewswire Inc. • 10/10/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 04:15:27 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM